ORPHA
vs
O
OMX Copenhagen 25
ORPHA
Over the past 12 months, ORPHA has underperformed OMX Copenhagen 25, delivering a return of 0% compared to the OMX Copenhagen 25's +2% growth.
Stocks Performance
ORPHA vs OMX Copenhagen 25
Performance Gap
ORPHA vs OMX Copenhagen 25
Performance By Year
ORPHA vs OMX Copenhagen 25
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Orphazyme A/S
Glance View
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.